Bristol-Myers Squibb Operating Income 2006-2019 | BMY

Bristol-Myers Squibb annual/quarterly operating income history and growth rate from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Bristol-Myers Squibb operating income for the quarter ending September 30, 2019 was $1.349B, a 37.75% decline year-over-year.
  • Bristol-Myers Squibb operating income for the twelve months ending September 30, 2019 was $6.609B, a 28.06% increase year-over-year.
  • Bristol-Myers Squibb annual operating income for 2018 was $5.968B, a 16.31% increase from 2017.
  • Bristol-Myers Squibb annual operating income for 2017 was $5.131B, a 13.25% decline from 2016.
  • Bristol-Myers Squibb annual operating income for 2016 was $5.915B, a 184.79% increase from 2015.
Bristol-Myers Squibb Annual Operating Income
(Millions of US $)
2018 $5,968
2017 $5,131
2016 $5,915
2015 $2,077
2014 $2,381
2013 $2,891
2012 $4,170
2011 $6,981
2010 $6,071
2009 $5,320
2008 $3,512
2007 $2,193
2006 $1,772
2005 $3,702
Bristol-Myers Squibb Quarterly Operating Income
(Millions of US $)
Q3 2019 $1,349
Q2 2019 $1,776
Q1 2019 $1,979
Q4 2018 $1,505
Q3 2018 $2,167
Q2 2018 $517
Q1 2018 $1,779
Q4 2017 $698
Q3 2017 $1,183
Q2 2017 $1,295
Q1 2017 $1,955
Q4 2016 $1,086
Q3 2016 $1,559
Q2 2016 $1,615
Q1 2016 $1,655
Q4 2015 $-410
Q3 2015 $987
Q2 2015 $52
Q1 2015 $1,448
Q4 2014 $-60
Q3 2014 $1,008
Q2 2014 $448
Q1 2014 $985
Q4 2013 $869
Q3 2013 $818
Q2 2013 $530
Q1 2013 $674
Q4 2012 $513
Q3 2012 $571
Q2 2012 $1,059
Q1 2012 $2,027
Q4 2011 $1,717
Q3 2011 $1,767
Q2 2011 $1,768
Q1 2011 $1,729
Q4 2010 $1,593
Q3 2010 $1,581
Q2 2010 $1,531
Q1 2010 $1,366
Q4 2009 $1,252
Q3 2009 $1,477
Q2 2009 $1,419
Q1 2009 $1,172
Q4 2008 $308
Q3 2008 $1,047
Q2 2008 $1,103
Q1 2008 $1,054
Q4 2007 $-292
Q3 2007 $870
Q2 2007 $852
Q1 2007 $763
Q4 2006 $-574
Q3 2006 $492
Q2 2006 $974
Q1 2006 $880
Q4 2005 $755
Q3 2005 $942
Q2 2005 $1,019
Q1 2005 $986
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $95.460B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $355.145B 15.39
Roche Holding AG (RHHBY) Switzerland $257.024B 0.00
Merck (MRK) United States $216.154B 16.75
Novartis AG (NVS) Switzerland $206.354B 17.42
Pfizer (PFE) United States $206.312B 12.26
Novo Nordisk (NVO) Denmark $135.639B 23.38
AbbVie (ABBV) United States $131.068B 10.27
AstraZeneca (AZN) United Kingdom $124.471B 22.48
Sanofi (SNY) France $115.466B 14.19
GlaxoSmithKline (GSK) United Kingdom $109.970B 13.32
Eli Lilly (LLY) United States $108.677B 20.07
Bayer (BAYRY) Germany $72.291B 10.71
H Lundbeck (HLUYY) Denmark $6.942B 10.02